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ABSTRACT 
The hallmark of fibrotic disorders is 
a highly cross-linked and dense collagen 
matrix, a property driven by the oxidative 
action of lysyl oxidase. Other fibrosis-
associated proteins also contribute to the 
final collagen matrix properties, one of 
which is fibromodulin - its interactions with 
collagen affect collagen cross-linking, 
packing, and fibril diameter. We 
investigated the possibility that a specific 
relationship exists between fibromodulin 
and lysyl oxidase, potentially imparting a 
specific collagen matrix phenotype. We 
mapped the fibromodulin-collagen 
interaction sites using the Collagen II and 
III Toolkit peptide libraries. Fibromodulin 
interacted with the peptides containing the 
known collagen cross-linking sites and the 
MMP-1 cleavage site in collagens I and II.  
Interestingly, the interaction sites are 
closely aligned within the quarter-staggered 
collagen fibril, suggesting a multivalent 
interaction between fibromodulin and 
several collagen helices. Furthermore, we 
detected an interaction between 
fibromodulin and lysyl oxidase – a major 
collagen cross-linking enzyme - and 
mapped the interaction site to 12 N-
terminal amino acids on fibromodulin. This 
interaction also increases the activity of 
lysyl oxidase. Altogether, the data suggest a 
fibromodulin-modulated collagen cross-
linking mechanism, where fibromodulin 
binds to a specific part of the collagen 
domain and also forms a complex together 
with lysyl oxidase, targeting the enzyme 
towards specific cross-linking sites. 
 
Dense collagen matrix in tendons and 
fibrotic collagen matrix in tumors and 
atherosclerotic plaques is enriched in a 
collagen-associated protein fibromodulin, 
FMOD (1-7). This protein is a member of 
small leucine-rich proteins whose temporo-
spatial expression patterns vary in different 
tissues and whose absence, in the respective 
knockout mice, creates tissue-specific collagen 
matrix phenotypes. Their differential 
expression and interactions with collagen is 
attributed to the different ways collagen 
matrices can be organized, reviewed here 
(8,9). FMOD itself influences collagen 
fibrillogenesis and cross-linking: Fmod-/- 
mouse tendons have a disturbed collagen fibril 
phenotype (1,10) and Fmod-/- tendon collagen 
has a lower acid extractability, excessively 
oxidized α1(I)-C-telopeptides and aberrantly 
cross-linked α2(I)-chains (11). Also, the 
morphological phenotype of Fmod-/- tendon 
collagen fibrils resembles the phenotype of 
fibrils where lysyl oxidase (LOX) - the major 
collagen cross-linking enzyme - is inhibited 
(12). FMOD might therefore be involved in 
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directing dense collagen cross-linking in 
tendons and fibrotic matrices, although the 
exact mechanisms are unknown. 
Collagen cross-linking depends on 
LOX and at least one of its homologues, 
LOXL2, that catalyze the oxidation of specific 
collagen lysines (13-18). Through oxidation 
lysines acquire reactive aldehydes that 
condense with other lysines, resulting in initial 
cross-link formation that becomes more 
complex as the collagens assemble into fibrils 
(19). LOX is activated through BMP-1 
processing of its inactive pro-isoform - a 
process potentiated by fibronectin (20) and 
further amplified by BMP-1 itself being 
incorporated into the fibronectin matrix 
through interaction with periostin (21). Once 
activated, LOX oxidizes lysine residues in 
collagen telopeptides (22,23) while binding to 
the collagen triple-helical domain (24); this 
process is more efficient on fibrillar rather 
than monomeric collagen (25,26) suggesting 
that proteins that specifically modulate 
collagen fibrillogenesis could also influence 
the specificity of LOX-mediated cross-linking. 
Through excessive cross-linking that imparts 
stiffness on the collagen matrix, LOX 
enhances fibrosis-enhanced metastasis (27-
29). Despite the dependence of collagen cross-
linking on the dynamics of fibril assembly and 
its restriction to specific collagen domains, 
research on potential modulators of these 
processes, especially in relation to LOX, has 
been scarce. Interestingly, LOX is not a 
collagen-exclusive enzyme but can oxidize 
other substrates, e.g. elastin, PDGF-R and 
TGF-β (30-32), raising the question of 
whether specific mechanisms exist that target 
LOX to collagen. Hypothetically, such 
proteins could modulate LOX activity in the 
extracellular space during the assembly of 
collagen fibrils. 
 In this paper, we hypothesized that 
FMOD could influence LOX activity near the 
collagen cross-linking sites, through binding to 
the specific collagen domains and/or through 
modulating LOX activity. To investigate this 
hypothesis, we mapped the collagen-binding 
sites of FMOD and tested and mapped the 
potential FMOD-LOX interaction. We also 
analyzed LOX quantity and distribution in 
Fmod-/- tendons and assayed LOX activity 
under the influence of FMOD. Our data, 
together with previously published findings, 
strongly suggest that FMOD can directly 
modulate site-specific LOX-mediated collagen 
cross-linking. 
 
EXPERIMENTAL PROCEDURES 
Materials – Collagen Toolkit peptides 
and their substituted variants were synthesized 
on TentaGel R Ram resin as C-terminal 
amides, using either an Applied Biosystems 
Pioneer or CEM Liberty peptide synthesizer, 
as previously described (33,34).  
The Collagen Toolkits II and III 
contain 56 or 57 peptides, each with 27 
residues of primary collagen sequence with 
neighboring peptides overlapping by nine 
amino acids, thus spanning the whole of the 
corresponding COL domain. The peptides are 
flanked by GPP(5) repeats and GPC triplets 
unless stated otherwise - these features impart 
stable triple-helical conformation on the entire 
peptide. 
 Collagen was extracted from mouse 
tail tendons using 20 mM acetic acid. 
Recombinant lysyl oxidase protein used in 
interaction assays was purchased from 
Origene. For transient expression of lysyl 
oxidase in 293T cells, for use in LOX activity 
assays, LOX cDNA was ligated into 
p3xFLAG-CMV-8 vector (Sigma), replacing 
the native signal peptide sequence with 
secretion pre-pro-trypsin leader sequence. 
Antibodies against lysyl oxidase (EPR4025) 
and against his-tag (18184) were from Abcam. 
Antibodies against fibromodulin were from 
Sigma (SAB1100690). 
Reagents – Biotin EZ-link reagent 
(ThermoFisher) was used to biotinylate 
recombinant fibromodulins using 
manufacturer’s instructions, then quenched 
with ethanolamine and dialyzed against TBS. 
Streptavidin-HRP was from Millipore. TMB 
substrate kit was from Pierce. 
Protein expression and purification – 
his-tag modified recombinant fibromodulin 
(human, amino acids 19-376) and its 
fragments (FMOD90, amino acids 31-376; 
FMODNT, amino acids 19-95) were expressed 
in 293T cells using pCEP4 vector (Invitrogen). 
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Proteins were purified on NiNTA sepharose 
(Qiagen) and further on Superose 6 (GE 
Healthcare) in PBS. Bacterial his-tagged 
FMOD was expressed in BL21 E.coli using 
pET27(b) vector (Novagen) and purified as 
follows: cells were lysed in 8M urea in 100 
mM NaH2PO4 and 100 mM Tris pH 8.0 (lysis 
buffer), the lysate was cleared by sonication 
and centrifugation, and the supernatant 
incubated with NiNTA sepharose. The 
sepharose was then washed in lysis buffer at 
pH 6.3, and fibromodulin was eluted in lysis 
buffer at pH 8.0 containing 250 mM 
imidazole. Fibromodulin was then dialyzed 
against PBS with 10% glycerol and gradually 
decreasing urea concentrations (from 8 M to 0 
M). In the final step the protein was purified 
on size exclusion chromatography using PBS. 
All steps were performed at 4 °C. All protein 
identities were confirmed by mass 
spectrometry. 
Collagen-binding assays – each assay 
included full-length collagen as positive 
control, and bovine serum albumin (BSA) and 
a GPP(10) triple-helical peptide, like the Toolkit 
flanking sequence, as negative controls. 
Collagen peptides were coated at 10 µg/mL in 
20 mM acetic acid overnight at 4 °C. Plates 
were rinsed three times with TBS, and blocked 
with 5% BSA in TBS for 1 h at room 
temperature. After blocking, plates were 
incubated with biotinylated fibromodulin at 10 
µg/ml in TBST with 0.1% BSA for 1 h. After 
washing with TBST, streptavidin-HRP was 
added at 1:10,000 dilution in TBST 0.1% BSA 
and incubated for 1h. After washing with 
TBST, the binding was detected with TMB 
substrate, stopped with 2 M sulfuric acid, and 
absorbance was read at 450 nm. 
Assays where fibromodulin binding to 
coated collagen I was tested in the presence of 
Toolkit peptides were performed using similar 
methods, but here acetic acid-extracted tail 
tendon mouse collagen I was diluted to 10 
µg/mL into PBS, distributed into a 96-well 
plate wells, and incubated at 37 °C for 1 h to 
induce fibril formation, and next incubated at 
4 °C overnight for coating.  Fibromodulin (10 
µg/mL) was pre-incubated for 2 h with Toolkit 
peptides of different concentrations before 
incubating with the coated collagen. 
Solid-phase binding assays - either 
lysyl oxidase or fibromodulin or its variants 
were coated overnight on a 96-well plate at 5 
µg/mL in sodium carbonate buffer pH 9.2. 
Collagen was coated at 10 µg/mL in PBS. The 
remaining part of the assay followed the 
protocol described above (collagen binding 
assays) but here binding of lysyl oxidase to 
coated fibromodulin proteins or collagen was 
detected with rabbit anti-lysyl oxidase and 
HRP-conjugated anti-rabbit antibody, and 
binding of fibromodulin proteins to coated 
lysyl oxidase or collagen was detected with 
mouse anti-his-tag and HRP-conjugated anti-
mouse antibodies. 
Immunohistochemistry - sections of 
paraffin-embedded tail tendons from wild-type 
and Fmod-/- mice were used. Antigen retrieval 
solution (L.A.B. solution from Polysciences) 
was used before quenching peroxidase with 
0.3% hydrogen peroxide for 15 min and 
blocking the sections with 10% goat serum in 
TBS for 1 h. Slides were incubated with anti-
fibromodulin (2 µg/mL in TBS and 1% serum) 
for 2 h, then washed with TBS, and stained 
with ultra-sensitive ABC rabbit IgG staining 
kit (Thermo Scientific) and diaminobenzidine 
peroxidase substrate kit (Vector Labs). 
Immunoblots - guanidine-extracted 
proteins from wild-type and Fmod-/- tendons 
were dissolved in urea/CHAPS solution and 
quantified using BCA assay (Thermo 
Scientific). 30 µg total protein was run on 4-
12% BisTris SDS-PAGE reducing gels 
(Thermo Scientific). Proteins were transferred 
to a nitrocellulose membrane that was 
immunoblotted using 5% milk in TBS for 
blocking, TBS with 0.1% Tween-20 for 
washing, and washing buffer with 0.5% milk 
for antibody incubations. Anti-lysyl oxidase 
was used at 1 µg/mL and HRP-conjugated 
anti-rabbit was used at 0.2 µg/mL. The 
antibodies were detected with SuperSignal 
West Dura (Thermo Scientific) and imaged 
using a charge-coupled device camera. 
Lysyl oxidase activity assays – fresh 
conditioned media (293 serum-free expression 
medium, Life Technologies) from 293T cells 
transiently expressing recombinant lysyl 
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oxidase (from p3xFLAG-CMV-8 vector) or 
mock control were used. Cells were 
transfected with either vector using 
Lipofectamine 3000, and medium was 
collected after three days. Aliquots of medium 
were incubated with recombinant 
fibromodulin or its fragments for 1 h before 
mixing with lysyl oxidase reaction buffer 
(Lysyl oxidase activity assay kit, Abcam). 
Samples were incubated for 15 min at 37 °C 
and LOX activity was measured by 
fluorescence detection 530/590 nm 
excitation/emission. 
Proximity ligation assays – Duolink 
PLA assays were purchased from Sigma and 
performed according to manufacturer's 
instructions. Here, we used HFL-1 cells 
seeded on coverslips and transfected with 
FMOD-pCEP his-tagged constructs (described 
above) or, as negative control, his-tagged non-
collagen binding domain of FMOD (LRR 
domains 1-3). His-tagged proteins were 
detected with mouse anti-his-tag. Endogenous 
LOX was detected with rabbit anti-LOX. 
Secondary antibodies coupled to DNA probes 
were included in the PLA assay kit. 
 
RESULTS 
Interaction of fibromodulin with Collagen 
Toolkit peptides – Because Fmod-/- tendons 
have an altered collagen cross-linking (11), we 
hypothesized that FMOD could modulate 
collagen cross-linking by interacting with 
specific cross-linking sites. To identify the 
binding sites we used Collagen II and III 
Toolkits in solid-phase assays. The assays 
showed FMOD affinity for the helix cross-
linking sites (peptides II-5, III-5, II-52, III-53 
in both Toolkits, Fig.1 A, B; both Toolkits 
were used contemporaneously). Other 
peptides, II-44 and III-44, containing the 
collagenase cleavage site or the peptide II-8 
earlier identified as an MMP interaction site 
(35,36) also had a high apparent affinity for 
FMOD (Fig.1 A, B). Finally, FMOD had no 
affinity for telopeptides (data not shown). 
 To validate our data, we tested the 
efficiency of Toolkit peptides in inhibiting 
FMOD-collagen type I interaction. We 
selected the peptides with the highest apparent 
affinity for FMOD, i.e. II/III-44, III-5, III-53, 
along with a negative control peptide II-26. In 
a solid-phase binding assay, the cross-linking 
site, peptides III-5 and III-53, could efficiently 
inhibit this interaction, while II/III-44 were 
only weak inhibitors, even at a 30-fold molar 
excess over FMOD (Fig. 1C). Combining II-
44 with III-5 or III-53 did not result in a higher 
inhibitory effect than when using these 
peptides alone (Fig. 1C, right). Also, III-53 
showed an inconsistent inhibitory effect in 
different experiments, while III-5 and II/III-44 
inhibitions gave similar results. 
 Sequences of the interacting Toolkit 
peptides are listed and aligned in Fig. 1D. 
Among the peptides that contain the known 
helix cross-linking sites the KGHR motif was 
the most obvious conserved sequence, making 
it a likely fibromodulin-binding site. 
Regarding peptides III-8, II-44 and III-44, a 
homologous pattern of arginine and 
hydroxyproline residues could be identified as 
a second, lower affinity, putative 
fibromodulin-binding site (Fig. 1D). This 
charge distribution is the only one occurring in 
Toolkits II and III. Aligning the II/III-44 
peptides with the respective sites on collagen I 
alpha chains shows a high degree of 
conservation in the α1(I) chain (only two 
conservative substitutions) and in α2(I) chain 
(slightly less conserved) (Fig. 1E). Regarding 
the helical cross-linking sites, they are all 
conserved in collagens I, II and III. 
 To test our hypothesis that FMOD 
interacts with the helical collagen cross-
linking site we tested the binding of FMOD to 
a peptide containing only this site (GLKGHR) 
and compared the binding with two mutated 
variants. As Fig. 1F shows, the interaction 
with the cross-linking site is high and depends 
on lysine: FMOD does not bind when lysine is 
alanine-substituted or acetylated. Also, 
arginine or histidine alone cannot compensate 
for the absence of lysine. 
Fibromodulin interactions with lysyl 
oxidase – Because of the collagen cross-
linking phenotype in Fmod-/- mice, we also 
hypothesized that FMOD may interact with 
LOX, an interaction that could modulate the 
accessibility of LOX to collagen and its cross-
linking sites. To identify potential FMOD-
LOX interactions we performed proximity 
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ligation assays on HFL-1 fibroblasts 
expressing his-tagged FMOD or his-tagged 
non-collagen-binding fragment of FMOD 
(negative control) and endogenous LOX. The 
assays detected an interaction between FMOD 
and LOX (Fig. 2A). 
 We wanted to identify the binding site 
of fibromodulin to LOX. Because we earlier 
identified the collagen-binding site to be in the 
LRR domain (37), we hypothesized that LOX 
binding could be in the N-terminal domain of 
FMOD. We therefore made a recombinant N-
terminal fragment of FMOD (FMODNT, 
amino acids 19-95), and truncated FMOD 
(FMOD90, amino acids 31-376) where we 
deleted the 12 N-terminal amino acids. We 
expressed the proteins in 293T cells, purified 
them (Fig. 2B) and used them in solid-phase 
assays. The assays show that LOX binds to 
full-length FMOD and to the N-terminal 
fragment (FMODNT), but not to the truncated 
FMOD90 (Fig. 2C,D). The binding to LOX is 
therefore sequestered to the N-terminal flank 
of FMOD, and the apparent KD of FMOD-
LOX interaction is ≅150 nM (Fig. 2E). We 
also analyzed if tyrosine sulfation on FMOD 
could affect this interaction: here we used 
bacterially expressed FMOD (lacking tyrosine 
sulfation) to assess its affinity for LOX. As 
Fig. 2F shows, the apparent affinity of LOX 
for FMOD with or without tyrosine sulfation 
is similar. Lastly, we also compared the 
relative affinities of FMOD and LOX for 
collagen. In our assay LOX affinity for 
collagen was low even at high molarity, 
whereas FMOD affinity for collagen had an 
apparent KD ≅ 250 nM (Fig. 2G). We also 
tested if FMOD could increase or inhibit 
LOX-collagen affinity but the data were 
inconclusive (not shown). 
Lysyl oxidase in fibromodulin-null 
mice – Because we detected an interaction 
between FMOD and LOX we then 
investigated if LOX processing, distribution, 
or quantity is altered in Fmod-/- mice. We 
used guanidine extracts from tail tendon tissue 
from wild-type and Fmod-/- mice to 
immunoblot for LOX. We could not detect any 
major deviation in quantity or processing of 
LOX in Fmod-/- mice; the latter was evident 
from observing only a 32 kDa band (processed 
LOX) but no 55 kDa pro-LOX band in either 
mice (Fig. 3A). Staining for LOX in tail 
tendon sections of wild-type and Fmod-/- mice 
did not reveal any obvious changes in 
distribution of LOX (Fig. 3B). 
Lysyl oxidase activity influenced by 
the N-terminal flank of fibromodulin – Next, 
we wanted to investigate if the presence of 
FMOD could stimulate or inhibit LOX 
activity. Unfortunately, we could not measure 
LOX activity directly in protein extracts from 
mouse tendons due to a very low signal. We 
therefore used conditioned cell culture 
medium from 293T cells overexpressing LOX 
and mixed it with different amounts of FMOD, 
FMOD90 or FMODNT. Here, we used fresh 
total cell culture medium from cells expressing 
LOX, as we observed that purification of this 
enzyme dramatically decreased its activity, as 
reported previously (38). Fig. 4 shows that 
addition of 1 µg full-length FMOD or the N-
terminal part of FMOD to LOX-containing 
medium can increase LOX activity: FMOD 
gives 62% (p<0.05) and FMODNT gives 47% 
(p<0.05) increase, while the truncated 
FMOD90 protein can achieve this effect only 
marginally (18%, N.S.). 
 
DISCUSSION 
We reasoned that FMOD could 
function as a LOX modulator during collagen 
fibrillogenesis because Fmod-/- mice tendons 
have an altered cross-linking pattern (11) and 
FMOD modulates collagen fibrillogenesis, i.e. 
when LOX is also recruited to collagen 
(1,6,25). Here, we present data that shows an 
FMOD interaction with collagen cross-linking 
sites, as well as an interaction of FMOD with 
LOX that results in increased LOX activity. 
This, together with the mentioned reports, 
supports a previously unknown role of FMOD 
as a LOX-modulating protein that can 
influence site-specific cross-linking of 
collagen. 
 FMOD, along with other homologous 
Small Leucine-Rich Proteins (SLRPs), has 
tissue-specific modulatory functions during 
collagen fibrillogenesis, these functions being 
evident in the different SLRP-deficient mice 
(8,39). Modulating fibril assembly could in 
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itself secondarily influence the LOX-mediated 
collagen cross-linking, but our data show that 
FMOD can exert this effect through direct 
binding to some of the collagen helix cross-
linking sites, of which there are two sites on 
each of the fibrillar collagens, represented here 
by peptides II-5, II-52 and III-5/6 and III-
52/53 (shown in Fig. 1A, B, D). While, all 
carry the putative KGHR binding sequence, 
the Toolkit peptides are not equivalent in the 
binding assays.  III-6 and III-52 have low 
thermal stability(33,34), 30 and 39 °C, 
compared with 47 °C for the Toolkits as a 
whole (DA Slatter, unpublished), perhaps 
accounting for their low FMOD binding. We 
have observed that the N-terminal site (peptide 
III-5) appears to have a higher affinity for 
FMOD, judged from the higher inhibitory 
effect of peptide 5 on the FMOD-collagen 
interaction (Fig. 1C). This might be explained 
by the influence of the neighboring amino 
acids and suggests a fine-tuned mechanism of 
cross-link modulation. We also observed that 
the lysine in the KGHR sequence is essential 
for binding of FMOD to the cross-linking site 
(Fig. 1F), suggesting also that FMOD may not 
bind to an already cross-linked site, i.e. when 
lysine has reacted with a telopeptide allysine. 
This would suggest FMOD involvement in 
collagen fibril assembly before cross-linking 
takes place. 
We also observe that FMOD binds 
peptides previously identified as MMP-
binding (peptides II-44 and III-44, Fig. 1A,B) 
(35,36) a site in both collagens that is adjacent 
to the cross-linking site on a neighboring 
tropocollagen molecule in a quarter-stagger 
assembled microfibril (Fig. 5A). Similarly, 
both these sites align with C-telopeptides (Fig. 
5) that are excessively oxidized by LOX in 
Fmod-/- mice (11). The span across the three 
sites (three tropocollagens) is approximately 5 
nm, which is roughly the size of the concave 
face of the LRR pocket in SLRPs (40,41), and 
it is tempting to suggest a multivalent binding 
of FMOD to two interaction sites (III-5, III-
44) across the three collagen helices (proposed 
in Fig. 5B). Therefore, FMOD could modulate 
collagen cross-linking by binding or possibly 
cross-bridging three collagen monomers 
around their cross-linking sites. Against this 
conclusion is the lack of potentiation of the 
inhibitory effect of both III-5 and III-44 on 
FMOD-collagen interaction; on the other 
hand, inhibition by III-5 alone is very efficient 
and any additive effect of III-44 may be 
marginal and hard to detect. Alternatively, 
bound FMOD could switch to an adjacent 
collagen monomer at some critical point 
during fibrillogenesis, thus switching from 
regulation of, perhaps, lateral assembly of 
collagens to regulation of cross-linking.  The 
discrepancy between solid-phase binding and 
ability of peptides to inhibit FMOD binding to 
collagen is intriguing.  Peptide III-5 supports 
strong FMOD binding and, in solution, blocks 
FMOD binding to collagen I.  In contrast, 
although II-44 and III-44 are also strong 
binders of FMOD, both only slightly inhibit its 
binding to collagen I. This suggests two 
binding modes, perhaps separate collagen-
binding sites on FMOD, a first, high-affinity 
site that recognises the KGHR sequence, and a 
second remote site that recognises the MMP-
interaction motifs in II-44 and III-44.  Whether 
allosteric or co-operative effects allow these 
sites to regulate one another remains to be 
established. 
Several other proteins besides FMOD, 
including fibronectin, fibrin, MMPs or 
collagen C-telopeptide bind to II/III-44 or its 
homologous site on collagen I (42-45). A cell 
might use such an overlapping interaction 
hotspot to differentially regulate collagen 
fibrillogenesis, cell adhesion or contraction. 
Within the sequence of II-44 (Fig 1E) binding 
of MMP13 to the canonical ¾-¼ cleavage site 
required residues spanning the first leucine 
and second arginine (35,36), and whilst the 
only residues critical for MMP1 binding were 
the two leucines, contacts were observed in the 
MMP1-peptide co-crystal including the next 
hydroxyproline (35,36), whilst fibronectin 
binding embraces the first and second arginine 
residues (44). In summary, the sites in 
collagens I and II that bind MMPs, FN and 
FMOD are not identical, but all overlap, and it 
would be anticipated that their binding would 
be mutually exclusive. 
To speculate on one example,  
C-telopeptide binding to the site that 
corresponds to II-44/III-44 stimulates collagen 
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fibrillogenesis (42,46). FMOD could, through 
binding to this site, delay fibrillogenesis that is 
stimulated by the C-telopeptide. In this 
manner, the C-telopeptide oxidation by LOX 
would also be delayed, because LOX activity 
increases on assembled collagen fibrils (25). 
Such a mechanism could explain the increased 
C-telopeptide oxidation in Fmod-/- mice (11), 
i.e. absence of FMOD would allow for a 
faster, uncontrolled, C-telopeptide-driven 
fibrillogenesis, thus triggering LOX to 
excessively oxidize C-telopeptides. 
Binding of FMOD to II-44/III-44 also 
supports the previous observation that FMOD 
can inhibit MMP cleavage of collagen (47). 
Such an interaction could protect collagen 
from being digested before it starts to 
assemble into fibrils. FMOD could of course 
also protect the already assembled fibers by 
shielding the II-44 site from MMP. 
 Our interaction data are largely in line 
with the previously reported interactions of 
FMOD with collagen I CNBr fragments (48). 
In this report, FMOD bound collagen fragment 
CB6 (that includes sequence from Toolkit 
peptide III-53), CB7 (includes III-44), and 
CB8 (includes III-8), but did not bind CB5, 
which contains the N-terminal helical cross-
linking site. The explanation for this 
discrepancy could be a conformational 
unfolding of the KGHR sequence: KGHR is 
preceded by a methionine where CNBr 
cleaves, and the cleavage would leave the 
KGHR site without flanking, helix-inducing 
GXY residues, likely to cause fraying of the 
new N-terminal end of the peptide, disrupting 
the binding site. 
 In the same paper (48) the authors also 
report on FMOD binding to collagen II CNBr 
fragments. CB9,7 fragment, containing the II-
52 sequence, was not used in the binding 
assay. One apparent discrepancy with our data 
is the absence of binding to CB10 (which 
contains the II-44 sequence) and binding to 
CB11 (where we have not found any binding). 
Here, one should consider that collagen II is 
more glycosylated, while Toolkit peptides are 
not – this could affect FMOD-collagen II 
interaction. Our data, as discussed above, 
point to conserved interaction sites across 
collagens I, II and III (Fig. 1E). 
 The binding of FMOD to collagen 
cross-linking sites suggested that FMOD 
might interact with the cross-linking enzyme, 
LOX. Indeed, we were able to identify their 
interaction in a fibroblast cell culture using 
PLA assays (Fig. 2A). We have mapped this 
interaction to the N-terminal 12 amino acids of 
FMOD (Fig. 2B-E) and observed no apparent 
effect of FMOD tyrosine sulfation on the 
interaction (Fig. 2F). We also observed that 
the binding of LOX to FMODNT was less 
pronounced than binding to FMOD (Fig. 2E); 
we think this could be due to a minor 
misfolding of FMODNT. 
Our data suggest that FMOD forms a 
complex with LOX and collagens, where LOX 
binds at one end of FMOD (as shown here) 
and collagen(s) bind in the LRR domain (37). 
We did, however, observe that FMOD 
increased LOX activity even in the absence of 
collagen and this activity depended on the N-
terminal tail of FMOD (Fig. 4). This activity 
increase may be considered marginal, and 
possibly we could have had obtained a more 
potentiating effect had we used purified lysyl 
oxidase rather than cell medium. In our hands 
though, purification or storage of LOX is 
detrimental to its activity (although its 
interaction with FMOD remains unaffected), 
and therefore we used fresh cell medium for 
the activity assay. There may, of course, be 
other components in the cell medium that 
affect the extent of FMOD-stimulated LOX 
activity. 
We suggest a model of  
FMOD-regulated collagen cross-linking where 
FMOD restricts premature fibril assembly and 
dysregulated cross-linking of collagens. This 
is achieved by binding to the surface of a 
collagen microfibril at its cross-linking site, 
while simultaneously binding LOX and 
directing its activity towards a specific lysine 
residue on an adjacent microfibril (Fig. 5B). 
Such an interaction may explain tissue-
specific cross-linking found in collagen 
matrices populated by FMOD, including 
tendons, ligaments, or fibrotic tissues. One 
should keep in mind that LOX-FMOD 
interaction does not ensure LOX-mediated 
cross-linking, but appears to direct it towards 
specific collagen lysine residues. 
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 Previously we reported excessive 
oxidation of collagen C-telopeptides in  
Fmod-/- mice (11). We have not detected any 
changes in LOX processing or quantity in 
Fmod-/- tendons, but we show here that 
FMOD interacts with LOX, changes its 
activity, and binds to collagen cross-linking 
sites. We reason that FMOD, by binding 
across the C-telopeptides, could shield LOX 
from excessively oxidizing telopeptides within 
one microfibril, a reaction that would prompt 
uncontrolled cross-linking between C-
telopeptide allysines, forming aldols 
interlinking other microfibrils. In FMOD-
controlled packing and cross-linking of 
microfibrils, LOX could be directed towards 
the telopeptides of another microfibril by 
binding to one end of FMOD, triggering the 
formation of a specific inter-fibril cross-link. It 
is also possible that LOX becomes positioned 
towards N-telopeptides in the same microfibril 
(Fig. 5B). This would ensure concerted, tissue-
specific packing of microfibrils into fibrils, 
and regulated intrafibrillar cross-linking. 
 In summary, our current and previous 
data show that FMOD can modulate LOX 
activity on specific sites on collagen, and 
support a novel theory regarding control of 
specific collagen cross-linking through 
collagen-associated proteins, likely crucial in 
the proper assembly of tendons but also of 
fibrotic collagen matrices. The exact cross-
links being formed in healthy and fibrotic 
tissues remain to be shown, as does the 
identity of the collagen-associated proteins 
that modulate their formation. This effort 
could open new perspectives and reveal new 
targets for treating fibrotic conditions. 
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FIGURE LEGENDS 
Figure 1. Identification of fibromodulin binding sites on collagen. Collagen Toolkit II (A) and 
Toolkit III (B) peptides were coated on a 96-well plate. The plate was blocked with BSA, and 
incubated with biotinylated FMOD at 10 µg/ml (170 nM) for 2 h. Binding was detected with 
streptavidin-HRP followed by TMB substrate, quenching with sulfuric acid, and measuring A450. 
BSA was used as a negative control. C. Inhibition of FMOD binding to coated collagen I. The 
assay was performed as above, but collagen I was coated on a 96-well plate, and FMOD was pre-
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incubated with increasing amounts of the interacting Toolkit peptides III-5, III-44, III-53, or with 
a negative control peptide II-26.  D. Sequences of the interacting Toolkit peptides are listed, with 
homologue amino acids underlined (except the repetitive glycines). The non-binding peptides are 
in italics. E. Homology alignment of FMOD-binding Toolkit peptides and the corresponding 
sequences on collagen I α1- and α2-chains. F. Solid-phase binding assay to assess interaction of 
FMOD with cross-linking site-containing collagen peptides and their mutated variants. The assay 
was performed as in A. Peptide sequences are listed on the x-axis (K(Ac) = acetylated lysine), 
except III-5 sequence that is listed in E. These shorter peptides were synthesised with GCP 
terminal triplets.  In A, B, C, F error bars represent standard deviation (n=3, technical replicates). 
All experiments were performed three times. 
  
Figure 2. Identification and characterization of FMOD-LOX interaction. A. Proximity 
ligation assay on HFL-1 cells expressing FMOD (left) or non-collagen-binding His-tagged 
FMOD fragment as negative control (right). Anti-His-tag and anti-LOX antibodies were used to 
detect the interaction (red fluorescence); nuclear staining with DAPI is blue. B. Gel image of 
FMOD variants used in the solid-phase assays in C-F. The proteins were expressed in 293T cells 
and purified on Ni-NTA sepharose. The amino acid range of each construct is listed. C. Solid-
phase assays showing interactions between FMOD variants and LOX. LOX was coated on a 96-
well plate, which was blocked with BSA, and incubated with 170 nM FMOD variants, whose 
binding was detected using anti-His-tag antibody. D. As in C, but here FMOD variants were 
coated on the plate followed by incubation with 150 nM LOX and detection with anti-LOX 
antibody. The experiments in C and D were repeated twice giving similar results. E. As in D. but 
here serial dilutions of LOX were used to determine apparent KD. Similar results were obtained in 
three experiments. F. Solid-phase assay to assess binding of LOX to coated FMOD (expressed in 
293 cells), bactFMOD (expressed in E. coli) and FMOD90. The assay was performed as in D. G. 
Solid-phase assay to compare binding of serially diluted FMOD and LOX to coated collagen in a 
96-well plate. Binding was detected using anti-His-tag or anti-LOX antibodies. Error bars in C-G 
represent standard deviation (n=3, technical replicates). Experiments in F and G gave similar 
results at three occasions. 
 
Figure 3. Lysyl oxidase quantity and distribution in Fmod-/- mice. A. Guanidine-extracted 
proteins from wild-type and Fmod-/- tail tendons were precipitated with ethanol, run on SDS-
PAGE, transferred to a nitrocellulose membrane, and stained with Ponceau, or detected with anti-
FMOD or –LOX antibodies (n=3, biological replicates). B. Immunodetection of LOX was 
performed on formalin-fixed tail tendons of wild-type and Fmod-/- mice. The sections were 
deparaffinized, hydrated, and processed for antigen retrieval and peroxidase quenching, before 
blocking with 10% goat serum and incubating with rabbit anti-LOX (or isotype control antibody) 
followed by HRP-conjugated anti-rabbit. The staining was developed using diaminobenzamidine 
peroxidase. 
 
Figure 4. Lysyl oxidase activity in the presence of fibromodulin. Lysyl oxidase activity was 
measured with a commercial kit. As a sample, conditioned medium from 293T cells expressing 
LOX (or from LOX-negative control cells) was used. The medium was pre-incubated for 1 h with 
FMOD or its variants and then mixed with the substrate and incubated for 15 min at 37 °C. 
Enzyme activity was measured by fluorescence emission at 590 nm after excitation at 530 nm. 
The plotted values are biological duplicates. Similar results were obtained in three independent 
experiments. 
 
Figure 5. Proposed model for collagen cross-linking modulation by fibromodulin. A. 
Alignment of the collagen III monomers is derived from 234-residue D-periods. The identified 
high-affinity FMOD-binding sites in collagen are marked in dark green (III-5), yellow (III-8), 
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blue (III-44), light green (III-53). D-periods are delimited with black lines. Collagen monomers 
are arranged in quarter-stagger, which reveals vertical alignment of III-44 and III-5 sites on 
neighboring collagen monomers. The two telopeptides (red) also align with FMOD-binding sites. 
B. Proposed binding of the FMOD-LOX complex to a microfibril. FMOD binds across three 
monomers, interacting with the vertically aligned collagen-binding sites. LOX binds to the N-
terminal end of FMOD and is positioned against the N-telopeptide in the microfibril. 
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